Here's why this ASX 200 healthcare share is racing 5% higher

This ASX 200 healthcare share is charging higher today…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Limited (ASX: RHC) share price is ending the week on a high.

In afternoon trade, the private hospital operator's shares are beating the ASX 200 index with a 5% gain to $62.02.

A doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

Why is the Ramsay share price beating the ASX 200?

Investors have been bidding the Ramsay share price higher on Friday following the release of the company's first quarter update.

According to the release, activity levels improved across all regions over the quarter compared to the prior corresponding period. Management advised that this reflects the decline in COVID cases in the community.

In light of this, the COVID impact on its profits in Australia and the UK fell from $44 million in July to just $5.9 million in September. The total impact across the quarter in these markets is estimated to have been $64.4 million.

Ramsay also revealed that it has been fighting rising costs. It advised that it is focused on negotiating improved terms with payors to reflect higher staffing costs related to labour shortages and inflationary pressures. Management notes that it finalised satisfactory new agreements with a number of private payors over the quarter.

This ultimately led to Ramsay reporting a 6.7% increase in revenue to $3,445.4 million and a 2.3% decline in EBITDA to $410.6 million for the first quarter.

Outlook

Pleasingly, this momentum has carried over into October, with Ramsay starting the second quarter positively. Looking ahead, management appears optimistic that it is onwards and upwards from here.

It commented:

The outlook for the Group remains strong as the business is well placed to take advantage of the positive long-term dynamics driving the healthcare industry. Ramsay expects a gradual recovery through FY23 and more normalised conditions from FY24.

The Ramsay share price remains down 13.5% in 2022 despite today's decline.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope around neck shrugging.
Earnings Results

CSL reports on 18 August. Can the healthcare giant arrest the slide?

A make-or-break result for Australia's fallen biotech giant.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Regis Healthcare acquires Royal Freemasons' Victorian home care business

Regis Healthcare has announced the acquisition of Royal Freemasons’ home care business, expanding its client base and annualised home care…

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

CSL vs Telix shares: Which is the better buy?

One valuation immediately caught my attention, while the other requires considerably more confidence in future growth.

Read more »

A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
Healthcare Shares

This ASX healthcare stock trades at its cheapest multiple in a decade

A quality business at a decade-low multiple. What gives?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

CSL shares bounced in July after a brutal year: What's next?

Can CSL sustain July's rebound when it reports FY2026 results this month.

Read more »

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »